Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics Inc (NASDAQ: TGTX) is a biopharmaceutical innovator advancing therapies for B-cell malignancies and autoimmune disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate strategies.
Access real-time announcements including trial results, FDA submissions, and partnership agreements. Our curated collection ensures you never miss critical updates about ublituximab (BRIUMVI), PI3K delta inhibitors, or emerging pipeline candidates.
Key content categories include quarterly earnings reports, scientific conference presentations, manufacturing updates. All materials are sourced directly from company filings and verified industry publications.
Bookmark this page for streamlined tracking of TGTX's progress in developing glycoengineered antibody therapies and maintaining compliance with financial disclosure requirements. Check regularly for authoritative updates on this NASDAQ-listed biotech pioneer.
TG Therapeutics (NASDAQ: TGTX) reported strong financial results for Q4 and full year 2024, with BRIUMVI U.S. net revenue reaching $103.6 million in Q4 and $310 million for the full year, marking approximately 250% growth year-over-year.
Key highlights include:
- Target guidance of $540 million in total global revenue for 2025
- Extended BRIUMVI patent protection through 2042
- Successful European launch with partner Neuraxpharm
- Impressive 5-year clinical data showing 92% of patients free from disability progression
The company reported net income of $23.3 million for Q4 2024 and $23.4 million for the full year. Cash position stands at $311.0 million as of December 31, 2024. R&D expenses increased to $94.3 million for 2024, while SG&A expenses rose to $154.3 million, primarily due to BRIUMVI commercialization efforts.
TG Therapeutics (NASDAQ: TGTX) presented data from multiple studies of BRIUMVI® (ublituximab-xiiy) for relapsing multiple sclerosis (RMS) at the ACTRIMS annual forum. The presentations included:
1. Updated results from the ENHANCE Phase 3b trial showing consistent safety and tolerability in over 80 patients receiving 30-minute maintenance BRIUMVI doses
2. A real-world retrospective chart review by Dr. John Foley examining over 160 BRIUMVI-treated patients, confirming safety profiles consistent with ULTIMATE I & II Phase 3 trials and noting improvements in patients with suboptimal responses to prior anti-CD20 therapies
3. Additional presentations on Fc Biology and Genetic Diversity study design, and disease activity trajectories comparison between ublituximab and teriflunomide in ULTIMATE trials
TG Therapeutics (NASDAQ: TGTX) has scheduled a conference call for Monday, March 3, 2025, at 8:30 AM ET to discuss their fourth quarter and full year 2024 financial results, along with providing a business outlook for 2025.
The call will be hosted by Michael S. Weiss, Chairman and Chief Executive Officer. Participants can join via phone using the following numbers:
- U.S.: 1-877-407-8029
- Outside U.S.: 1-201-689-8029
A live webcast will be available on the Events page in the Investors & Media section of www.tgtherapeutics.com, with an audio recording accessible for 30 days after the call. Financial results will be released via press release before the call.
TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations of BRIUMVI® (ublituximab-xiiy) data at the ACTRIMS annual forum, scheduled for February 27 – March 1, 2025, in West Palm Beach, Florida. The presentations will showcase results from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial in patients with relapsing forms of multiple sclerosis (RMS).
Four poster presentations are scheduled, including studies on: the safety and tolerability of 30-minute ublituximab infusions from the ENHANCE study; Fc biology and genetic diversity in multiple sclerosis; real-world ublituximab experience at a US MS center; and disease activity trajectories comparing ublituximab and teriflunomide in ULTIMATE I and II trials.
TG Therapeutics (TGTX) announced preliminary Q4 and full-year 2024 results for BRIUMVI®, reporting strong U.S. net product revenue of $103.6 million and $310 million respectively. The company projects ambitious 2025 targets, including total global revenue of approximately $540 million, with BRIUMVI U.S. net product revenue expected to reach $525 million.
With a year-end 2024 cash position of approximately $310 million, TG Therapeutics plans significant development initiatives for 2025, including launching pivotal programs for subcutaneous BRIUMVI administration and optimizing intravenous dosing. The company targets operating expenses of approximately $300 million for 2025 and plans to expand BRIUMVI's evaluation in autoimmune diseases beyond Multiple Sclerosis.
TG Therapeutics (NASDAQ: TGTX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chairman and CEO, Michael S. Weiss, is scheduled to deliver a presentation on Monday, January 13, 2025, at 4:30 PM PT.
Investors and interested parties can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website. For those unable to attend the live presentation, a replay will be made available on the company's website following the event.
TG Therapeutics (NASDAQ: TGTX) has announced its participation in the 7th Annual Evercore HealthCONx Conference. The event will be held at the Loews Coral Gables Hotel in Florida from December 3-5, 2024. Michael S. Weiss, the Company's Chairman and CEO, will participate in a fireside chat on Tuesday, December 3, at 10:00 AM ET. Interested parties can access a live webcast of the discussion through the Events page in the Investors & Media section of the company's website.
TG Therapeutics (NASDAQ: TGTX) has been ranked number one on the 2024 Deloitte Technology Fast 500™, which recognizes the fastest-growing companies in North America across technology, media, telecommunications, life sciences, fintech, and energy tech sectors. The company's exceptional growth between fiscal years 2020-2023 was driven by BRIUMVI® revenues, their multiple sclerosis treatment approved in December 2022 for adult patients with relapsing forms of the disease.
TG Therapeutics reported strong Q3 2024 financial results with BRIUMVI net revenue of $83.3 million, representing 15% quarter-over-quarter growth and 230% year-over-year increase. The company raised its full-year 2024 BRIUMVI revenue guidance to $300-305 million. Clinical data showed impressive 5-year results with 92% of patients free from disability progression and an annualized relapse rate of 0.02. The company secured FUJIFILM Diosynth as a secondary US manufacturer and reported Q3 net income of $3.9 million with a strong cash position of $341 million.
TG Therapeutics (NASDAQ: TGTX) has scheduled a conference call for Monday, November 4, 2024, at 8:30 AM ET to discuss their third quarter 2024 financial results and provide a business outlook. The call will be hosted by Chairman and CEO Michael S. Weiss. Financial results will be released before the call. Participants can join via phone (1-877-407-8029 U.S., 1-201-689-8029 international) or watch the live webcast on the company's website. An audio recording will be available for 30 days after the call.
FAQ
What is the current stock price of Tg Therapeutics (TGTX)?
What is the market cap of Tg Therapeutics (TGTX)?
